Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera, and in nearly two-thirds of low-risk patients, according to a retrospective study. Srdan Verstovsek, MD, of the MD Anderson Cancer Center, and colleagues conducted the research and published their findings in Annals of Hematology. ...
Advertisement
Ponatinib plus hyper-CVAD led to "excellent" outcomes in patients with newly diagnosed Ph+ ALL.
A chemotherapy-free regimen with ponatinib and blinatumomab led to high complete molecular response rates in Ph+ ALL.
A triplet may improve PFS over lenalidomide alone in patients with multiple myeloma who underwent induction and AHSCT.
Low-risk MDS can have high-risk features, but current MDS prognostic scoring systems may not capture key risk variables.
A new method to detect MRD in peripheral blood had an “unprecedented sensitivity” level in multiple myeloma.
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPSagar Lonial, MD, FACP, of the Winship Cancer Institute, is Editor-in-Chief of Blood Cancers Today.
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Expert Interviews
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
American Society of Hematology
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
Raul Cordoba, MD, PhD
Raul Cordoba, MD, PhDKey Points. Fully automated classification of mature
flowcytometry
hematology
lymsm
Frontiers
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
Benlazar S M A
Benlazar S M AAllogeneic stem cell transplantation still represent
aml
leusm
finance.yahoo.com
FDA Puts Clinical Hold On Gilead’s Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MSThe FDA has placed a partial clinical hold on Gilead
leusm
mdssm
medRxiv
Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional
Michael Hallek
Michael HallekBackground Long COVID is a post-severe acute respira
longcovid
ACUTE MYELOID LEUKEMIA
AGGRESSIVE B-CELL LYMPHOMA
CHRONIC LYMPHOCYTIC LEUKEMIA
MYELOMA
ACUTE MYELOID LEUKEMIA
